|
|
|
|
| |
128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Tags
-
Traversa Raises $2 Million in Angel-Led Series A Financing
Traversa Therapeutics, Inc., a privately held developer of RNAi delivery technologies, announced recently the completion of a $2 million Series A financing led by the San Diego Tech Coast Angels and joined by investors Mesa Verde Venture Partners and Morningside Group.
Traversa was founded with technology developed by Professor Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego (UCSD) relating to siRNA delivery and the induction of RNA Interference (RNAi).
“There is a great need for novel short interfering RNA (siRNA) delivery platforms. This technology has shown outstanding delivery characteristics in pre-clinical models, as well as in vitro delivery to nearly all cell types and entire cell populations assayed in a non-cytotoxic fashion. These cell types include primary cells, T cells, B cells, Macrophage, huESC and tumor cells, where other delivery approaches have failed,” noted Dr. Dowdy, co-founder of Traversa.
“We are very pleased with the impact that our investors have already made in developing new opportunities for the company,” said Hans A. Petersen, President and CEO of Traversa. “The technology has received an outstanding level of interest for use with human therapeutics, and as a high throughput screening reagent, providing the company with both long-term growth prospects and a short-term revenue stream to augment this financing. Traversa is currently being evaluated by several large pharmaceutical companies to treat diseases of the eye and nose, metabolic diseases, cancer and infectious diseases.”
Dr. Francois Ferre, co-CEO of Althea Technologies and lead angel investor, has joined the board. Both Dan Wood of Mesa Verde Venture Partners and Roger Flugel of Sanderling Ventures are board observers. Sanderling Ventures and a Morningside Group entity are limited partners of Mesa Verde Venture Partners.
Traversa Therapeutics, Inc. is a La Jolla, California-based bio-pharmaceutical company engaged in the discovery, development and commercialization of RNAi delivery technologies. The company strives to rapidly advance siRNA platform delivery technologies for use internally and by other pharmaceutical companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa also markets its technology for high throughput RNAi screening applications.
For more information, please visit www.traversathera.com
Leave a reply
Latest Headlines:
Thursday September 02, 2010
Hub Angels and RRE Ventures Lead $1.9 Million in Series A Funding for Copiun
Tuesday August 31, 2010
VC Firm, Draper Triangle Ventures Invest $5 Million in Series B Funding for ClearCount Medical Solutions
Monday August 30, 2010
PrairieGold Venture Partners Joins Sanderling Venture Partners, vSpring Capital, and Mesa Verde Venture Partners to Add $5 Million to Complete a $10.8 Million Series A Funding Round for Lineagen
Thursday August 26, 2010
Investment Firms, Partech International, El Dorado Ventures, and Sisco Systems Lead $10 Million Investment in Series C Funding for Atlantis Computing
Tuesday August 24, 2010
Mirimar Venture Partners Leads $20 Million in Series C for Brand Affinity Technologies to Promote Celebrity Endorsement and Engagement Business
Monday August 23, 2010
Intersouth Partners Invests $3 Million in 6fusion as Company Relocates to North Carolina
Monday August 16, 2010
ITC Holdings and Kinetic Ventures Lead $18 Million Funding Round In Growth Capital for Cardlytics
Friday August 13, 2010
New Energy Capital Closes $100 Million in First Clean Tech Infrastructure Fund
Bad Behavior has blocked 246 access attempts in the last 7 days.
